

Critical Care Ebola Virus Disease

Dr Brian Marsh

Consultant in Intensive Care Medicine

Chair ICSI Advisory Group EVD

Mater Misericordiae University Hospital

November 2014



Tom E. Fletcher
Robert A. Fowler
Nicholas J. Beeching

Understanding organ dysfunction in Ebola virus disease






Figure 3. Haemorrhagic manifestations noted in non-human primates infected with Ebola virus
Petechiae on the arm and axillary region of a Cynomolgus monkey infected with Sudan Ebola virus (A). Also shown are haemorrhages in the ileum (B) and a gastroduodenal lesion (C) from a Cynomolgus monkey infected with Sudan Ebola virus and fibrin thrombi (arrows) in sinusoids of a rhesus monkey infected with Zaire Ebola virus (D).

Ebola Virus Disease in West Africa — Clinical Manifestations and Management

Daniel S. Chertow, M.D., M.P.H., Christian Kleine, M.D., Jeffrey K. Edwards, M.D., M.P.H., Roberto Scaini, M.D., Ruggero Giuliani, M.D., and Armand Sprecher, M.D., M.P.H.

PERSPECTIVE

EBOLA VIRUS DISEASE IN WEST AFRICA

| Clinical Features of Ebola Virus Disease. | | |
|---|--------------------------|--|
| Phase of Illness | Time since Symptom Onset | Clinical Features |
| Early febrile | 0–3 days | Fever, malaise, fatigue, body aches |
| Gastrointestinal | 3–10 days | Primary: epigastric pain, nausea, vomiting, diarrhea Associated: persistent fever, asthenia, headache, conjunctival injection, chest pain, abdominal pain, arthralgias, myalgias, hiccups, delirium |
| Shock or recovery | 7–12 days | Shock: diminished consciousness or coma, rapid thready pulse, oliguria, anuria, tachypnea Recovery: resolution of gastrointestinal symptoms, increased oral intake, increased energy |
| Late complications | ≥10 days | Gastrointestinal hemorrhage, secondary infections, meningoencephalitis, persistent neurocognitive abnormalities* |

* Secondary infections are presumptive diagnoses based on clinical features of distributive shock, oral or esophageal candidiasis, and oral ulcers; meningoencephalitis is a presumptive diagnosis based on clinical features of unconsciousness and stiff neck.

ORIGINAL ARTICLE

Clinical Presentation of Patients with Ebola Virus Disease in Conakry, Guinea

Elhadj Ibrahima Bah, M.D., Marie-Claire Lamah, M.D., Tom Fletcher, M.R.C.P.,
Shevin T. Jacob, M.D., M.P.H., David M. Brett-Major, M.D., M.P.H.,
Amadou Alpha Sall, Ph.D., Nahoko Shindo, M.D., Ph.D., William A. Fischer II, M.D.,
Francois Lamontagne, M.D., Sow Mamadou Saliou, M.D.,
Daniel G. Bausch, M.D., M.P.H.&T.M., Barry Moumié, M.D., Tim Jagatic, M.D.,
Armand Sprecher, M.D., James V. Lawler, M.D., M.P.H., Thierry Mayet, M.D.,
Frederique A. Jacquerioz, M.D., María F. Méndez Baggi, M.D.,
Constanza Vallenás, M.D., Christophe Clement, M.D., Simon Mardel, M.D.,
Ousmane Faye, Ph.D., Oumar Faye, Ph.D., Baré Soropogui, Pharm.D.,
Nfaly Magassouba, D.V.M., Ph.D., Lamine Koivogui, Pharm.D., Ph.D.,
Ruxandra Pinto, Ph.D., and Robert A. Fowler, M.D.C.M.

Table 2. Therapies Received by 37 Patients Hospitalized for EVD.

| Therapy | Value |
|--|----------|
| Oral rehydration solution — no. (%) | 36 (97) |
| Intravenous fluids — no. (%) | 28 (76) |
| Median volume of crystalloid solution administered in first 24 hr (IQR) — liters | 1 (1–1) |
| Antibiotic treatment — no. (%) | |
| Any | 37 (100) |
| Ciprofloxacin | 20 (54) |
| Ceftriaxone | 13 (35) |
| Cefixime | 5 (14) |
| Amoxicillin–clavulanic acid | 1 (3) |
| Antimalarial treatment — no. (%) | 7 (19) |
| Supplemental oxygen therapy — no. (%) | 1 (3) |

Table 3. Clinical Complications and Outcomes for 37 Patients with EVD.

| Variable | Value |
|--|----------|
| Hospital mortality — no. (%) | 16 (43) |
| Median length of stay in hospital (IQR) — days | 8 (6–11) |
| Known complications in hospital — no. (%) | |
| Hemorrhage | |
| Any | 19 (51) |
| Gastrointestinal | 9 (24) |
| Subconjunctival | 4 (11) |
| Intravenous catheter site | 4 (11) |
| Nasorespiratory tract | 2 (5) |
| Renal failure* | 2 (5) |
| Seizure | 2 (5) |
| Oral candidiasis | 1 (3) |
| Hypoxemia | 1 (3) |

* Renal failure was defined as a serum creatinine level of more than 4 mg per deciliter (350 μ mol per liter).

Bah et al NEJM Nov 2014

BRIEF REPORT




A Case of Severe Ebola Virus Infection Complicated by Gram-Negative Septicemia

Benno Kreuels, M.D., Dominic Wichmann, M.D., Petra Emmerich, Ph.D.,
Jonas Schmidt-Chanasit, M.D., Geraldine de Heer, M.D., Stefan Kluge, M.D.,
Abdourahmane Sow, M.D., Thomas Renné, M.D., Ph.D., Stephan Günther, M.D.,
Ansgar W. Lohse, M.D., Marylyn M. Addo, M.D., Ph.D., and Stefan Schmiedel, M.D.

Table S2: Physical examination on admission



| | |
|------------------------|--|
| VITALS | H: 179 cm, W: 75 kg. GCS 15/15, SpO ₂ 97%, RR 110/80, HR 87 bpm |
| GENERAL | Awake and responsive, ambulatory without assistance. |
| HEENT | No scleral icterus or conjunctival bleeding. Pupils isochroous and reactive to light and accommodation. No enanthema. Dry mucosal membranes. |
| NECK | Supple, no abnormalities detected |
| HEART AND LUNGS | auscultation and percussion not possible. ¹ |
| ABDOMEN | Soft, mild tenderness to palpation, percussion and auscultation not possible. ¹ |
| EXTREMITIES | No edema, erythema or calf pain bilaterally. |
| SKIN | No rashes noted on extremities, chest, abdomen, or back. No petechia or purpura. |
| NEUROLOGICAL | Able to stand, walk and moving all extremities, no focal neurological deficits, CN II-XII grossly intact. limited exam. |

¹Due to the personal protective equipment worn in the unit, the use of stethoscopes was not possible and there were some limitations to full physical examination.



↑
Hamburg day 1 / day 10 illness

Benno et al. NEJM Oct 2014



Benno et al. NEJM Oct 2014



Figure S4. Chest X-ray on day of illness 16

Compared to the image taken on day of illness 15, bedside CXR shows newly developed bilateral pleural effusions, increased cardiac congestion and atelectasis. A gastric tube displayed in correct anatomic position.

+ blood aspiration

NIV for 8 days from
day 18 of illness

$\text{SaO}_2 < 85\%$ x 5 days

Table S3: Ultrasound examination on admission


| | |
|---|--|
| LIVER | normal aspect and size without focal lesions, no cholestasis, all liver vessels with orthograde flow. |
| SPLEEN | normal aspect and size |
| KIDNEYS AND BLADDER | both kidneys of normal aspect and size, no obstruction of the urinary tract |
| INTESTINAL TRACT | pronounced edema of the stomach, small intestine and large intestinal wall. Extremely distended intestinal loops, with large amounts of intra-intestinal fluids and complete absence of peristaltic movement |
| LYMPH NODES | mesenterial lymph nodes enlarged |
| ABDOMINAL VESSELS | complete collapse of the inferior Vena Cava (IVC) |
| No signs of pericardial effusion, pleural effusion or ascites | |

Canadian Critical Care Society
Canadian Assoc. of Emergency Physicians
Assoc. of Medical Microbiology & Infectious Diseases Canada

Ebola Clinical Care Guidelines

A guide for clinicians in Canada

**Report #2 – Updated:
October 28, 2014**



Organized by the Public Health Agency of Canada

Treatment

The mainstay of treatment is supportive care, which includes careful attention to intravascular volume status and oral or intravenous fluid therapy, correction of electrolyte and metabolic abnormalities, correction of coagulation abnormalities, nutritional support, and antibiotics for secondary bacterial infections. Although robust data are still lacking, anecdotal experience from EVD patients treated both Africa and 'Western' health care systems during the current outbreak suggests that the mortality rate associated with EVD can be significantly reduced through the provision of supportive care, and in particular critical care.

**Information
for
Critical Care Management of the Adult Patient
In Ireland with
Ebola Virus Disease 2014**

Report of:

**Critical Care Advisory Group on Ebola Virus Disease
Intensive Care Society of Ireland**

Interim Guidelines 28th October 2014

(to be updated with evolving international guidelines)

www.icmed.com

Advisory Group

| | |
|----------------------------------|--|
| Dr B Marsh | Chair ICSI Advisory Group Mater Misericordiae University Hospital |
| Dr C O'Loughlin | Mater Misericordiae University Hospital |
| Dr J Moriarty | St. James's Hospital |
| Dr I M-Loeches | St. James's Hospital |
| Dr D Collins | St. James's Hospital |
| Dr G Fitzpatrick | Adelaide and Meath Hospital Dublin |
| Dr M Donnelly | Adelaide and Meath Hospital Dublin |
| Dr A Westbrook | St.Vincent's University Hospital |
| Dr P Neligan | University College Hospital Galway |
| Dr M Power | Beaumont Hospital |
| Dr R Dwyer | Beaumont Hospital |
| Dr R Plant | Cork University Hospital |
| Dr V Hamilton | University Hospital Waterford |
| Dr C Nix | University Hospital Limerick |
| Dr J O'Dea | University Hospital Limerick |
| Dr K Carson | Children's University Hospital, Temple St. |

The information in this document is designed to draw together available guidelines and information to assist the critical care clinical teams access relevant materials. Best clinical practice remains the responsibility of each doctor caring for these patients. When better information becomes available regarding specific therapies for this disease in an ICM context, these shall be added to this information resource.

Critical Care Scope

Context:

Full PPE training and NIU environment training

Specialist Roles:

Critical Care Medicine - advice, assessment, early intervention
and prevention of organ failures,
diagnostic (eg. US), procedural (eg.CVC)

Critical Care Nursing - skill mix re level 2 / 3 ICM

| Symptom | Aetiology | Management | Procedural |
|---------------------------------|---|---|---|
| Hypotension and shock | Hypovolaemia 2° to GI losses; secondary infection; SIRS | Close fluid balance. Aggressive fluid resus. Electrolyte replacement K, Ca. Assess fluid responsiveness. Consider Vasopressors. | Consider CVC <ul style="list-style-type: none"> - K+ replacement - Vasopressors - Difficult IV access - ScvO₂ Ultrasound Guided Senior Clinician |
| Severe vomiting / diarrhoea | Early in disease | NGT Ondansetron Haloperidol Metoclopramide ? Rectal tube | Caution re NGT and/or faecal collection system with coagulation abnormalities |
| Dyspnoea or Respiratory Failure | Late in disease. | O ₂ ?NIV ?Intubation & mechanical ventilation. ? Bacterial infection ? Blood aspiration | Adjunctive Strategies Hepa filtration <ul style="list-style-type: none"> - Ambu / C-Circuit - Expired gasses Senior Clinician Protective ventilation strategies. |
| Seizure / Coma | Ominous and late | Medical management of seizures. Check Na ⁺ , glucose | |
| Intolerant of PO | Vomiting | Enteral Nutrition if tolerated Parenteral Nutrition | PN usually mandates CVC |

| Symptom | Aetiology | Management | Procedural |
|-------------------|---|--|---|
| Renal failure | Hypovolaemia. DIC | Close fluid balance. Aggressive fluid resus. ? CRRT ? IHD | Vascath. Considerations: CRRT Complexities IHD case suitability CDC Guidelines re dialysis Ultrasound Guided Senior Clinician |
| Liver dysfunction | Common in severe cases. Maybe early in disease | Monitor LFTs Coagulation Consider Vit K Beware hypoglycaemia | |
| Haemorrhage | Late in disease. DIC | Correct coagulation abnormalities. Target Hb 7g/dl Blood Bank EVD protocol | |
| CPR | | Patient Context Patient wishes | Ability to provide safe and effective CPR |
| Pain | Abdomen, joint, chest wall | Symptomatic medical | |










ICU Team




Patient resuscitative / care needs unique but identifiable and within skillmix.

Environment and PPE – Complex

Ideally, one center only.




Recommended Hospital Groups



Critical Care Programme Critical Care 'hub-and-spoke' Model


Tús Áite do
Shábháilteacht **1** Othar
Patient Safety **1** First



CCS = Critical Care Service



Critical Care Retrieval- safe inter-hospital
critically ill patient transport



Critical Care Retrieval EVD

Volunteer Consultant Rota
Based from Dublin
Collaborative Training
Critical Care Referral

Critical Care EVD “hub & spoke”

